ANI Pharmaceuticals ANIP Generics and Other — Net Revenues

Similar metrics at other companies

BLCOBranded and Other Generics — Total revenues

$49M-9.3%

AMRXOther dosage forms — Net revenue

$46.61M-17.4%

AMRXOther therapeutic classes — Net revenue

$13.95M+115%

BCRXProduct sales, net — Total revenues

$151.4M+5.3%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

ACIPharmacy — Net sales and other revenue

$2.69B+18.9%

Questions, answered.

What is ANI Pharmaceuticals's generics and other — net revenues?

ANI Pharmaceuticals (ANIP) reported generics and other — net revenues of $109.22M in Q1 2026.

How has ANI Pharmaceuticals's generics and other — net revenues changed year-over-year?

ANI Pharmaceuticals's generics and other — net revenues increased by 6.0% year-over-year, from $103.04M to $109.22M.

What is the long-term trend for ANI Pharmaceuticals's generics and other — net revenues?

Over 3 years (2022 to 2025), ANI Pharmaceuticals's generics and other — net revenues has grown at a 19.3% compound annual growth rate (CAGR), from $235.24M to $399.43M.

What does generics and other — net revenues mean?

Represents the total gross sales of generic pharmaceutical products and related services within the specified business segment, net of returns, allowances, and rebates. This metric serves as a primary indicator of market demand and the competitive positioning of the company's generic drug portfolio.